Predictors Affecting Long-term Use of Solifenacin or Mirabegron in Women With Overactive Bladder Syndrome

Far Eastern Memorial Hospital500 enrolled

Overview

A retrospective analysis of medical records at Far Eastern Memorial Hospital from January 2008 to May 2020 about female patients with overactive bladder syndrome, who received Solifenacin or Mirabegron as the initial treatment. Factors affecting persistence of OAB medications will be analyzed.

Study Type

OBSERVATIONAL

Enrollment

500

Conditions

Overactive Bladder Syndrome

Interventions

Solifenacin Oral TabletDRUG

Solifenacin 1 tablet per day

Mirabegron 25mgDRUG

Mirabegron 1 tablet per day

Eligibility

Sex: FEMALEMin age: 20 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Women with overactive bladder syndrome received solifenacin or mirabegron as the initial treatment Exclusion Criteria: * \<20 year-old

Locations (1)

Department of Obstetrics and Gynecology, Far-Eastern Memorial Hospital

Banqiao District, New Taipei, Taiwan

RECRUITING

Outcomes

Primary Outcomes

Predictors of persistence of mirabegron versus solifenacin use

Time frame: 13 years

Central Contacts

Sheng-Mou Hsiao, MD

CONTACT

+886919302632 smhsiao2@gmail.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.